OBJECTIVE: To date, data regarding the determinants of mortality in HIV-infected patients starting antiretroviral therapy (ART) in Africa have been primarily derived from routine clinical care settings practicing the public health approach. Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality. METHODS: We evaluated HIV-infected adults initiating ART between January 1, 2004 and September 30th, 2007 in an ART clinic in southwestern Uganda. Clinical and demographic characteristics were obtained through routine clinical care. In evaluating determinants of mortality, a 'naïve' analysis used only deaths known through routine processes. A 'sample-corrected' approach incorporated, through probability weights, outcomes from a representative sample of patients lost to follow-up whose vital status was ascertained through tracking in the community. RESULTS: In 3,628 patients followed for up to 3.75 years after ART initiation, the 'naïve' approach identified male sex and lower pre-ART CD4 count as independent determinants of mortality. The 'sample-corrected' approach found lower pre-ART CD4 count, older age, lower weight and calendar year of ART initiation, but not male sex, to be independent determinants of mortality. CONCLUSIONS: Analyses to identify determinants of mortality in HIV-infected patients on ART in Africa that do not account for losses to follow-up can identify spurious associations and miss actual relationships - both with the potential to mislead public health efforts. A sampling-based approach to account for losses to follow-up represents a feasible and potentially scalable method to strengthen the evidence available for implementation of ART delivery in Africa.
OBJECTIVE: To date, data regarding the determinants of mortality in HIV-infectedpatients starting antiretroviral therapy (ART) in Africa have been primarily derived from routine clinical care settings practicing the public health approach. Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality. METHODS: We evaluated HIV-infected adults initiating ART between January 1, 2004 and September 30th, 2007 in an ART clinic in southwestern Uganda. Clinical and demographic characteristics were obtained through routine clinical care. In evaluating determinants of mortality, a 'naïve' analysis used only deaths known through routine processes. A 'sample-corrected' approach incorporated, through probability weights, outcomes from a representative sample of patients lost to follow-up whose vital status was ascertained through tracking in the community. RESULTS: In 3,628 patients followed for up to 3.75 years after ART initiation, the 'naïve' approach identified male sex and lower pre-ART CD4 count as independent determinants of mortality. The 'sample-corrected' approach found lower pre-ART CD4 count, older age, lower weight and calendar year of ART initiation, but not male sex, to be independent determinants of mortality. CONCLUSIONS: Analyses to identify determinants of mortality in HIV-infectedpatients on ART in Africa that do not account for losses to follow-up can identify spurious associations and miss actual relationships - both with the potential to mislead public health efforts. A sampling-based approach to account for losses to follow-up represents a feasible and potentially scalable method to strengthen the evidence available for implementation of ART delivery in Africa.
Authors: Kara Wools-Kaloustian; Silvester Kimaiyo; Lameck Diero; Abraham Siika; John Sidle; Constantin T Yiannoutsos; Beverly Musick; Robert Einterz; Kenneth H Fife; William M Tierney Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: E Florence; J Lundgren; C Dreezen; M Fisher; O Kirk; A Blaxhult; G Panos; C Katlama; S Vella; A Phillips Journal: HIV Med Date: 2003-07 Impact factor: 3.180
Authors: Elvin H Geng; David R Bangsberg; Nicolas Musinguzi; Nneka Emenyonu; Mwebesa Bosco Bwana; Constantin T Yiannoutsos; David V Glidden; Steven G Deeks; Jeffrey N Martin Journal: J Acquir Immune Defic Syndr Date: 2010-03 Impact factor: 3.731
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Elvin H Geng; David V Glidden; David R Bangsberg; Mwebesa Bosco Bwana; Nicholas Musinguzi; Denis Nash; John Z Metcalfe; Constantin T Yiannoutsos; Jeffrey N Martin; Maya L Petersen Journal: Am J Epidemiol Date: 2012-02-03 Impact factor: 4.897
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196
Authors: Njoroge Anne; Matthew D Dunbar; Felix Abuna; Peter Simpson; Paul Macharia; Bourke Betz; Peter Cherutich; David Bukusi; Farquhar Carey Journal: Int J Med Inform Date: 2019-10-18 Impact factor: 4.046
Authors: Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Gregory P Bisson Journal: Addiction Date: 2016-09-07 Impact factor: 6.526
Authors: Catherine A Koss; Paul Natureeba; Dalsone Kwarisiima; Mike Ogena; Tamara D Clark; Peter Olwoch; Deborah Cohan; Jaffer Okiring; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731